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ABSTRACT
N,N-dimethyl-n-octadecylamine borane 1 at 8 mg/kg/day, tetrakis-u-(trimethylamine
boranecarboxylato)-bis(trimethyl-carboxyborane)-dicopper(I I) 2_ at 2.5 mg/kg/day and
trimethylamine-carboxyborane 3 at 8 mg/kg/day were evaluated for their effects on bile lipids, bile
acids, small intestinal absorption of cholesterol and cholic acid and liver and small intestinal
enzyme activities involved in lipid metabolism. The agent administered orally elevated rat bile
excretion of lipids, e.g. cholesterol and phospholipids, and compounds 2 and 3 increased the bile
flow rate. These agents altered the composition of the bile acids, but there was no significant
increase in lithocholic acid which is most lithogenic agent in rats. The three agents did decrease
cholesterol absorption from isolated in s#u intestinal duodenum loops in the presence of drug.
Hepatic and small intestinal mucosa enzyme activities, e.g. ATP-dependent citrate lyase, acyl
CoA cholesterol acyl transferase, cholesterol-7-c-hydroxylase, sn.glycerol-3-phosphate acyl
transferase, phosphatidylate phosphohydrolase, and lipoprotein lipase, were reduced. However,
the boron derivatives 1 and 3 decreased hepatic HMG-CoA reductase activity, the regulatory
enzyme for cholesterol synthesis, but the compounds had no effects on small intestinal mucosa
HMG-CoA reductase activity. There was no evidence of hepatic cell damage afforded by the
drugs based on clinical chemistry values which would induce alterations in bile acid concentrations
after treatment of the rat.
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INTRODUCTION
Previously we have demonstrated that certain boron derivatives are potent hypolipidemic agents
in rats at dose ranges of 2.5-20 mg/kg/day. [1-3] These agents demonstrated significant
reductions in both rat serum cholesterol and triglyceride levels after 14 days administration.
Perhaps more importantly, selected derivatives were able to lower cholesterol content of VLDL
and LDL, and elevate HDL cholesterol levels in rats [4]. Preliminary acute toxicity studies have
demonstrated that these agents have no deleterious side effects based on organ weights, clinical
chemistry levels, hematopoietic parameters and histological examination of major organs of mice
and rats [5]. Initial studies on the bile indicated that lipid content was modulated by drug therapy
with increases in cholesterol and phospholipid content after 14 days [1-3]. Clinical treatment with
hypolipidemic agents have produced cholelithiasis or cholestasis. Therefore, a detailed analysis
of rat bile lipid and bile acids after treatment with these agents was addressed along with studies
on lipid regulatory enzyme activities and lipid distribution to clarify the characteristics of these
agents on bile excretion and intestinal metabolism.
MATERIALS AND METHODS
N,N-Dimethyl-n-octadecylamine borane I was synthesized according to the literature preparation
of Hall et al. [1]. Tetrakis-u-(trimethylamine-boranecarboxylato)-bis(trimethylamine-
carboxyborane)-dicopper(ll) 2 was prepared by the method of Hall et al. [2]. Trimethylamine-
carboxyborane 3 was synthesized as outlined by Hall et al. [3]. Drugs were prepared in 1%
carboxymethylcellulose and homogenized. Control animals were maintained on 1%
carboxymethylcellulose as a vehicle treated group. All isotopes were purchased from New
England Nuclear. Substrates and cofactors were obtained from Sigma Chemical Co., and HPLC
column and eluants were obtained from Waters Millipore Co.
Bile Cannulation Studies: Sprague Dawley male rats (~ 300g) were administered compounds 1,
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were administered chlorpromazine (25 mg/kg) and anesthetized 30 min later with pentobarbital
(22 mg/kg i.p.) [2], a combination which reduces the amount of pentobarbital necessary to
maintain anesthesia level over extended periods of time without bronchial spasms. An incision
was made just below the rib cage to expose the stomach and the duodenum. Once the bile duct
was identified, a loose ligature was placed around it and the duct was nicked. PE-10 plastic tubing
was placed in the duct and tied in place. The bile was collected from the control and treated
groups over the next 6 hours while the animals were maintained under anesthesia.
Bile Lipid Levels: The flow rate of the bile was calculated for each group as ml/min. Aliquots
were extracted for lipids by the Folch et al. [6] and Bligh and Dyer [7] methods. Cholesterol [8],
triglyceride [Bio-Dynamics/bmc triglyceride kit], neutral lipids [9], and phospholipid content [10]
was determined. Protein concentrations were also determined [11]. For HPLC analysis of bile
acids content, samples were frozen overnight. After thawing the bile lipids were extracted with
EtOH [1:20] and filtered [12]. Aliquots (250 ul) of the bile were added to 10 #1 of the intemal
standard (testosterone). Then 4.75 ml of hot analytical grade ethanol was added, vortexed, and
allowed to evaporate in a boiling water bath. The residues were dissolved in 250 ul of the mobile
phase A [acetonitrile-methanol-0.03 M phosphate buffer, pH 3.4 (10:60:30 v/v/v)] and 100 ul was
injected onto the HPLC column Bondapak C18 column) (30 cm x 3.9 mm ID) 0Naters) with a
guard column (Bondapak C18/Corasi) (Naters) eluted with mobile phase A. The flow rate was 0.5
ml/min (600 psi isobaric flow) with detection at 210 nm. Standard bile acids (Sigma Chemical
Co.) were purchased and were treated identical as the bile biological samples.
Absorption from In Situ Duodenum Loops: Sprague Dawley male rats were treated orally and
anesthesized as indicated above and the duodenum was isolated and nicked. Glass L-shaped
cannulae were placed at the proximal end of the duodenum and 20 cm distally down the intestine
[13]. The segment was perfused with isotonic PBS Isotope buffer, pH 7.2 until the lumen was
clear and all material expelled. Drug solution (0_.2 ml) (2.5-8 mg/kg) was placed in the loop with
either 1,2-3H- cholesterol (54.8 Ci/mol) or 2,4-5H- cholic acid (25 mCi/mol) Isotope. An aliquot
(2uCi) was also placed in the loop. Aliquots (50ul) were periodically removed over the next 210
min and the radioactivity determined using a Packard scintillation counter after correcting for
quenching. The disappearance of the isotope from the loop over time was plotted for the control
and treated animals.
In Vivo 3H-Cholesterol or _3H Cholic Acid Absorpti..on: Sprague Dawley mal_e rats (~280g) after
being treated 14 days_with boron derivatives were administered 10uCi of 1,2-H-cholesterol (54.8
Ci/mol) orally or 2,4-;H-cholic acid (25 mCi/mol) in PBS, pH 7.2, 24 hrs prior to sacrifice [14]. The serum, liver, spleen, small intestine and large intestine mucosa, chyme and a 24 hr fecal
specimen were collected. A 10% homogenate of each tissue was prepared in 0.25 M sucrose +
0.001 M EDTA and radioactivity was determined. DPMs were calculated for each total organ.
Heoatic and Small .!.ntestinal Enzymatic Studies: Sprague Dawley male rats (~280 g) were
administered drugs 1, 2 or 3, orally for 14 days. On day 15, the animals were sacrificed and the
liver and small intestinal mucosa were excised. Homogenates (10%) in 0.25 M sucrose + 0.001 M EDTA, pH 7.2 were prepared of the liver and small intestinal mucosa [15]. The following enzyme assays were determined by literature techniques: ATP dependent citrate lyase [16], acetyI-CoA
synthetase [17], HMG-CoA reductase [18, 19], acyI-CoA-cholesterol-acyl transferase [20], neutral-
cholesterol-ester-hydrolases [21], cholesterol-7-cx- hydroxylase [22], acetyI-CoA carboxylase [23], sn-glycerol-3-phosphate acyl transferase [24], phosphatidylate phosphohydrolase [25] and
lipoprotein lipase [26].
Clinical Chemistry Levels: Blood was collected from the control and treated rats from the
abdominal vein after lightly anesthetizing the animal with ether. Sigma chemistry kits were used to analyze SGPT (no. 505), glucose (no. 510) alkaline phosphatase (AP no. 104) LDH (no. 500), and direct bilirubin (no 605). Bile salts and uric acid were determined by the method of Tietz [27]. The animals were killed by carbon dioxide asphyxiation. After all vital signs had ceased, a mid-
line incision was made from the lower jaw to the inguinal area. Thymus, spleen, liver and kidney were excised and weighed. Representative tissue samples were fixed in 10% buffered formalin,
trimmed and sectioned at 6u in thickness and stained with hematoxylin and eosin. Data displayed
in Tables I-VI represent means + standard deviations. The Student’s "t" test was applied between
control groups and the individu drug treatment groups. The analysis of variance (ANOVA) was
applied among test drugs and is reported in the text only.
RESULTS
Treatment with boron derivatives 2 and 3 for 14 days in rats resulted in an increase in the flow rate of the bile whereas compound 1 aused a significant decrease, although the effects of
compound 2 were not significant. Corpound 1-3 caused increases in cholesterol content in the
bile. CompOunds 1-3 caused marked increase- bile phospholipids. Only compound 2 caused
elevated levels of"glyceride content of the bile (Table I). Neutral lipids in the bile were not
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affected by any of the drug treatments. Protein content of the bile was elevated by compound 2
and 3. Analysis of the bile acids after treatment with compound 1, 2_ and 3_ showed that the total
bile acids were either increased by drug treatment with 2 but significantly reduced by drug
treatment with 1_ and 3_.(Table II). The ratio of the bile acids were altered in absolute
concentration. Compound 1_ caused a decrease in taurodeoxycholic acid, taurocholic,
tauroclenodeoxycholic acid and glycoursodeoxycholic acid levels with an increase in
tauroursodeoxycholic acid, glycocholic acids and glycochenodeoxycholic acid content.
Compound 2 caused a significant increase in tauroursodeoxycholic acid and glycoursodeoxycholic
acid. All other bile acids except taurochenodeoxycholic acid levels were markedly reduced by
treatment with compound 2. Compound 3 caused an increase in tauroursodeoxycholic acid, and
glycochenodeoxycholic acid content with reduction of all other bile acids except taurocholic acid
content.
Table I. The Effects of Boron Derivatives on Bile Lipids of Sprague Dawley Rats Orally for 14
Days
Percentage of Control (X + SD)
(N 6) Control Compound i Compound 2 Compound 3
Bile flow rate i00 + 4a 50 + 3* 119 + 4 151 + 4*
Cholesterol 100 + 5b 160 + 6* 111.+ 8 145 + 4*
Triglycerides I00 +/- 7c 87 +/- 4 238 +/- 9* 106 +/- 6
Neutral lipids 100 +/- 8d 104 +/- 6 101 +/- 7 98 +/- 5
Phospholipids i00 +/- 7e 176 +/- 9* 878 +/- 12" 184 +/- 6*
Protein 100 + 5f 99 + 4 153 + 7 150 + 6
a 0.62 ml/hr d 1.7 mg/ml
b i. 18 mg/ml e i. 75 mg/ml
c 0.5 mg/ml f 0.0334 mg/ml
* p <_ 0.001 Student’s "t" test
Table II. HPLC Analysis of Bile Acid from Sprague Dawley Rat Treated for 14 Days Orally
with Boron Derivatives
Percentage of Control (X + SD)
(N 6) Control Compound I Compound 2 Compound 3
Tauroursodeoxycholic Acida
Glycoursodeoxycholic Acid#b
Taurocholic AcidC
Glycocholic Acidd
Taurodeoxycholic Acide
Lithocholic Acidf
Taurochenodeoxycholic Acidg
Glycochenodeoxycholic Acidh
Total Bile Acids(mg/ml)
100a + 3 124 +.3" 262 + 6* 136 + 5*
100b + 6 60 + 6 163 + 5* 27 + 3
100c + 4 0 + 3* 0 + i* 97 + 4
100d + 7 138 + 3* 0 + 2* 63 + 4*
100e + 6 5 + 2* 0 + 3* 0 + i*
100f + 6 98 + 4 40 + 4* 37 + 3
100g + 5 I0 + 6 I00 + 5 0 + 2*
100h + 7 22 + 6 0 + i* 144 + 6*
3.28+0.58 i0.68+0.73 16.93+0.84 7.89+53
a 2.50 #g/ml e 0.50 #g/ml
b 5.61 #g/ml f 2.52 #g/ml
c 1.53 #g/ml g 0.24 #g/ml
d 0.62 #g/ml h 0.09 #g/ml
[glycoursodeoxycholic acid plus
tauro-beta muricholic acid]
* p <_ 0.001
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The isolated intestinal loop study showed that when the boron derivatives were present at their
therapeutic dose, they retarded the absorption of cholesterol from the lumen over 3.5 hr (Table
III). Compounds 1 and 3_ inhibited the absorption of cholesterol by 50% of that observed in the
control. Compound 3 exhibited even_ greater reduction in absorption at 180 min (ANOVA, p <
0.05) than compounds I and 2. The ;H-cholic acid absorption from the loop was not as severel
retarded by the three agents over 3.5 hr (Table IV). Compound I moderately reduced the amount
of cholic acid absorption from the intestinal loop.
Table III. The Effects of Boron Derivatives on 3H-Cholesterol Absorption from Isolated Intestinal
Loops from Sprague Dawley Rats.
(N = 6)
Percentage Radioactivity in Intestinal Lumen (X +/- SD)
Time (min) Control Compound 1 Compound 2 Compound 3
0 i00 + 5a i00 + 5 I00 + 7 I00 + 5
30 70 + 5* 76 + 3 75 + 4 90 + 6
60 43 + 5* 69 + 3* 58 + 5* 57 + 7
90 35 + 6* 64 + 4* 41 + 7* 74 + 8*
120 29 + 4* 64 + 5* 36 + 2* 96 + 4*
150 22 + 3* 60 + 6* 44 + 8* 97 + 5*
180 21 + 4* 85 + 9* 48 + 3* Iii + 6
210 i0 + 3* 88 + 5* 58 + 3* iii + 3
a 240 dpm/50 ml * p _< 0.001
Table IV. The Effects of Boron Derivatives on 3H-Cholic Acid Absorption from Isolated
Intestinal Loops from Sprague Dawley Rats
Percentage Radioactivity in Intestinal Lumen (X + SD)
(N = 6)
Time (min) Control Compound 1 Compound 2 Compound 3
0 i00 + 4a I00 + 4a I00 + 5a I00 + 5a
30 68 + 6* 73 + 3* 66 + 6* 70 + 4*
60 45 + 5* 39 + 2* 46 + 4* 34 + 7*
90 24 + 3* 28 + 7* 30 + 3* 13 + 2*
120 i0 + 2* 29 + 7* 33 + 6* 15 + 4*
150 5 + 2* 35 + 3* 26 + 4* 13 + 3*
180 2 + I* 36 + 9* i0 + 4* 6 + 2*
210 1.5 + I* 45 + 6* 7 + I* 2 + i*
a 460 dpm/50 I * p< 0.001
These data suggest that in vivo the boron derivatives interfere with absorption of cholesterol and
possibly cholic acid as well as the enterohepatic circulation of these bile acids.
Examination of the hepatic and small intestinal mucosa enzyme activities demonstrated that all
three compounds inhibited significantly hepatic ATP-dependent citrate lyase, acetyI-CoA
synthetase, acyI-CoA-cholesterol-acyl transferase, and sn-glycerol-3-phosphate acyl transferase
(Table V). Hepatic phosphatidylate phosphohydrolase activity was reduced by compound 2
significantly and moderately by compound 3. HMG-CoA reductase activity was inhibited in liver
cells by compounds 1 and 3. Compound 1-3 caused a reduction of hepatic cholesterol-7-c-
hydroxylase activity. Cholesterol-ester-hydrolase activity was elevated by compounds 1 and 2.
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Hepatic lipoprotein lipase activity was suppressed by compound 2 and 3. Small intestinal mucosa
ATP-dependent citrate lyase activity was suppressed by compounds 1 and 2. HMG-CoA
reductase activity was not significantly inhibited by any of the compounds. AcyI-CoA-cholesterol-
acyl-transferase activity was reduced in the intestinal mucosa by 1_ and 2 but was elevated in the
presence of compound 3. Small intestinal mucosa lipoprotein lipase activity was inhibited by
compounds I and 2.
Table V. The Effects of Boron Derivatives on Sprague Dawley Male Rats
Orally for 14 Days on Hepatic and Small Intestinal Mucosa
Enzyme Activities
Percentage of Control (X + SD)
N=6) Liver
Enzyme Assay Control Compound i Compound 2 Compound 3
ATP-dependent-citrate lyase
AcetyloCoA synthetase
HMG-CoA reductase
Acyl-CoA-cholesterol-acyl
transferase
Cholesterol-esterohydrolase
Cholesterol-7e-hydroxylase
Acetyl CoA carboxylase
sn-Glycerol-3ophosphate acyl
transferase
i00 + 4a 7 + 4* 25 + 6*
100 + 5b 4 + 2* 33 + 5*
100 + 6c 50 + 7* 128 + 6*
i00 + 5d 36 + 2* 34 + 2*
i00 + 6e 128 + 7* 135 + 7*
I00 3f 69 7* 54 4*
I00 +/- 4g 94 +/- 7 84 +/- 6
i00 + 5h 39 + 3* 34 + 3*
Phosphatidylate phosphohydrolase i00 + 6i 106 + 6 27 + 6*
Lipoprotein lipase I00 + 5j 127 + 4* 72 + 5*
19 + 3*
22 + 3*
55 + 6*
56 + 8*
107 + 7
71 + 7*
85 + 8
44 + 5*
85+6
53 + 5*
(N-- 6 ) Small Intestinal Mucosa
Enzyme Assay Control Compound I Compound 2 Compound 3
ATpodependent-citrate lyase
AcetyloCoA synthetase
HMG-CoA reductase
Acyl-CoA-cholesterol-acyl
transferase
Cholesterol-ester-hydrolase
Cholesterol-7-hydroxylase
Acetyl CoA carboxylase
sn-Glycerol-3-phosphate acyl
transferase
i00 + 5k 45 + 7* 32 + 7* 90 + 4
100 + 61 88 + 6 66 + 5* 78 + 5*
I00 + 7m 117 + 8 93 + 6 87 + 8
i00 + 4n 51 + 8* 45 + 4* 138 + 9*
100 + 6o 237 + 6* 63 + 4* 87 + 6
I00 + 4P 65 + 5* 18 + 2*
100 +/- 6q 99 +/- 5 83 +/- 9 101 +/- 8
I00 + 4r 16 + 4* 88 + 6 17 + 4*
Phosphatidylate phosphohydrolase I00 + 6s 53 + 6*
Lipoprotein lipase I00 + 6t 74 + 4*
56 + 5* 112 + 6
45 + 6* 105 + 7
Control values for 60 min/gm wet tissue" a 9.2 mg citrate hydrolyzed; b
i0.0 mg acetyl CoA formed; c 103020 dpm; d 86640 dpm; e 22443 dpm; f
289450 dpm; g 43000 dpm; h 87620 dpm; i ii #g Pi released j 3112 dpm k
9.17 mg citrate hydrolyzed 1 5.27 mg acetyl CoA formed; m 113322 dpm; n
64819 dpm; o 23199 dpm; p 259099 dpm; q 54892 dpm; r 73219 dpm; s 114 #g
Pi release; t 43128 dpm. * p <_ 0.001
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Table Vl. Effects of Boron Derivatives on Selected Clinical Chemistry
Levels of Sprague Dawley Male Rats After 14 Days Orally
Percentage of Control (X + SD)
Blood Enzymes Control Compound i Compound 2 Compound 3
SGPT (46.3 m/ml) i00 + 6
LDH (102 IU/I) i00 + 5
Bilirubin (direct)
(0. i mg/dl) I00 + 7
Alkaline phosphatase
(15 m/l) i00 + 6
Bile Salts i00 + 6
Uric Acid (1.5 mg/dl) i00 + 5
Glucose (158 mg%) I00 + 7
* p<_ 0.001
109 + 5 106 + 4 87 + 4
86 + 3 99 + 3 80 + 7
95 + 6 104 + 6 99 + 6
98 + 6 89 + 6 75 + 5*
108 + 4 103 + 5 92 + 3
85 + 3 96 __+ 4 44 + 5*
88 + 57 92 + 5 I01 + 6
When clinical chemistry enzymes and levels were measured in the blood to determine liver
function, there were no significant increases in serum bilirubin (direct), glucose, SGPT, LDH, bile
salts, or uric acid in any of the sera from treated rats (Table VI). Histological examination of the
selected organs after treatment for 14 days with compound 1 demonstrated that the thymus,
kidnay and spleen sections were normal. The liver sections showed mild intracytoplasmic
vacuolation and capsular reactory hyperplasia with moderate mixtures of acute and chronic
inflammatory cells. After treatment with compound 2 the spleen and thymus sections were normal.
The liver sections showed increased cytoplasmic vacuolation especically around the central vein.
There was one small nidus of acute inflammation of the hepatic capsule. The parenchyma cells of
the kidney were normal but there was focal capsulitis and congestion. Compound 3 treatment
resulted in no abnormalities of the thymus, kidney, spleen or liver. The control vechicle treated
sections of the liver demonstrated scattered collections of mononuclear cells among the hepatic
cell cords. The kidney, spleen and thymus sections from the vechicle treated rats were all normal
in morphology.
DISCUSSION
The hypolipidemic agents nafedopin [28] and clofibrate [29] increased the bile flow of rats.
Similarly the trimethylamine carboxyborane 3 and dicopper complex 2 increased bile flow in
treated rats after 14 days. The addition of boron derivatives into the lumen of the intestine of rats
was effective in decreasing the absorption of cholesterol from intestinal loops, suggesting that the
drug is effective in blocking the absorption of cholesterol consumed orally in the diet as well as
enterohepatic recirculating cholesterol and possibily cholic acids from bile excretion. Previous
studies with boron derivatives have shown that orally administered 3H-cholesterol to intact treated
rats is reduced in the blood after 24 hrs compared to that of control animals [1-3] indicating similar
findings after in vivo administration of the boron derivatives. Since a good percentage of the
hepatic bile acids are derived from enterohepatic circulation, this mechanism of the drugs would
ultimately lower serum cholesterol levels as observed with all three of these agents similar to the
clinical hypolipidemic agents colestipol and cholestyramine resins. A direct relationship between
the increase in bile acid concentration and bile flow has been noted in rats and monkeys [30].
Certain bile acids are choleretic in rats, for example dehydrocholic acid > chenodeoxycholic acid
> cholic acid > taurocholic acid > deoxycholic acid > glycocholic acid. Even though boron
derivatives increase the concentration of certain bile acids, there did not appear to be a positive
correlation with the effects of boron derivatives on increased levels of known choleretic bile acids
and the observed increase in bile flow for compounds 2 and 3. It should be noted that the
cannulation technique diverts the bile from the common bile duct. Removing the bile from the
intestine could alter the GI mucosa hormonal regulation of pancreatic and gastric mucosa
secretion. Thus, these animals may be in a non-physiological state over the 6 hr period. The
effects of boron derivatives on GI mucosa hormone secretions were not determined in this study;
thus, it is unknown if the drugs altered their levels.
Since hypolipidemic agents, e.g. clofibrate, gemfibrozil and estrogen are known to be lithogenic
causing increased incidence of gall stones [31,32]. When used clinically, the effect of boron
derivatives as hypolipidemic agents require evaluation in this regard. The boron derivatives
altered the concentration of the selected individual bile acids. However, it should be noted that
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none of the three agents significantly increased lithocholic acid, which in rats has the highest
choleretic activity. Tauro- and glycolithocholates are less potent cholestatic agents in rats
followed in order by taurodeoxycholate, taurochenodeoxycholate, and taurocholate in rats [33].
The lack of significant increases in any of these three bile acids which would suggest that these
boron derivates are not lithogenic at 2.5-8 mg/kg/day for 14 days. No unidentified bile acids were
noted in the treated rats in this study. Gall stone formation has been linked with high levels of
hepatic HMG-CoA reductase activity and low level levels of cholesterol-7-a- hydroxylase activity
[29]. In rats it has been observed that the rate of hepatic cholesterol synthesis, the levels of
cholesterol esters regulated by acyI-CoA-acyl-transferase activity and the amount of cholesterol
absorbed from the intestine play no role in cholesterol secretion into the bile [29]. As observed in
the liver enzyme study, the boron derivatives did not demonstrate enhanced hepatic HMG-CoA
reductase activity at doses employed. Compounds 2 did increase HMG-CoA reductase activity in
the liver 28% but not in the small intestinal mucosa cells. All of the compounds decrease hepatic
cholesterol-7-- hydroxylase activity at their respective doses. This is the rate limiting enzyme for
the conversion of free hepatic cholesterol to bile acids. In addition, we were able to determine a
relatively high concentration of this enzyme in the rat small intestine mucosa cells which was also
reduced by drugs I and 2 treatment. AcyI-CoA-cholesterol-acyl transferase activity was reduced
and cholesterol-ester-hydrolase activity was increased by the three compounds, which should
increase the free cholesterol level in the hepatic cell. A good correlation was evident when the
drug altered these enzyme activities creating increased level of liver cell free cholesterol and the
observed increase of biliary cholesterol levels in treated rats. Another factor in gall stone
formation is the insolubility of cholesterol since it is the main component of the stone. Cholesterol
is maintained in solution as a mixed micelle consisting of bile acid, cholesterol and phospholipid.
Only compounds 2 increased overall bile acid concentrations particularly tarurodeoxycholic acid.
Although it should be noted that the bile flow was actually elevated slightly and bile phospholipid
concentration was exceedingly high after treatment with this agent. Compound 2 appears to have
the greatest potential to be lithogenic but other factors, i.e. the high phospholipid content, may
counter its ability to cause gall stones. Compounds 1_-3 increased bile phospholipid levels. An
increase in bile acid content is related more directly with gall stone formation rather than
reductions in phospholipid content in the bile [33]. Estrogen, which is also a hyperlipidemic agent,
causes chlolestasis [34] and increases plasma alkaline phosphatase levels indicative of hepatic or
other tissue damage. Treatment with the three boron derivatives demonstrated no significant
changes in the clinical chemistry values to suggest that the agents damaged the liver cells.
Morphological changes were confined to the liver with some changes in the vehicle treated control
suggesting some type of mild hepatitis infection of all of the rats and the effects were probably not
related to specific drug treatment.
In conclusion, there are significant changes in bile acid composition after treatment with boron
derivatives; nevertheless, they do not appear to be lithogenic in nature. The boron derivatives
were very effective in increasing biliary cholesterol and phospholipids and thus their elimination
form the body since they were not reabsorped. There did not appear to be any morphological
lesions or damage to the liver induced by the compounds when administered orally. Thus, the
agents did not seem to induce any damage to the hepatic cells which would suggest that they
were interfering with their physiological function.
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